Tetraphase Pharmaceuticals Names Garen Bohlin to Board of Directors to Advance Strategic Interests and Broaden Corporate D

– Bohlin to provide strategic leadership to optimally leverage the company’s full range of corporate development opportunities –

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against drug resistant bacteria, including multidrug-resistant (MDR) gram negative pathogens, today announced that it has appointed Garen Bohlin to its Board of Directors, effective immediately. Mr. Bohlin will provide strategic leadership with the board, working closely with management as the Company seeks to advance its market-leading antibiotics franchise.

“Garen is renowned for building value for innovative biotechnology companies and then successfully leveraging that value to achieve an optimal outcome,” said Guy Macdonald, Chief Executive Officer of Tetraphase. “With his experience and knowledge of the marketplace, we believe he will be able to help guide Tetraphase to comparable success, all the while helping us realize the full potential of our portfolio of novel antibiotics.”

Mr. Bohlin has held senior executive posts in leading biotechnology companies for the past 25 years. Most recently he served as Chief Operating Officer of Sirtris Pharmaceuticals, where he played key roles in the overall management of Sirtris, its initial public offering and the sale of the company to GlaxoSmithKline for more than $700 million. Prior to his role at Sirtris, Mr. Bohlin was the founding Chief Executive Officer of Syntonix Pharmaceuticals where he positioned the company for its sale to Biogen Idec. He began his career in the biotechnology sector at Genetics Institute, where he held multiple executive positions culminating with responsibility for most of the non-scientific areas, and played an integral role in structuring the sale of Genetics Institute to American Home Products (Wyeth) at an implied valuation of approximately $3 billion. Mr. Bohlin was a partner at Arthur Andersen & Co. before assuming various operating roles in the life sciences field. Mr. Bohlin currently serves as Executive Vice President at Constellation Pharmaceuticals, a leading epigenetics biopharmaceutical company.

“Tetraphase is an exciting company that has leveraged its ground-breaking synthetic chemistry technology to rapidly build a market-leading antibiotics franchise,” said Mr. Bohlin. “Tetraphase’s pipeline consists of a complementary portfolio of IV and oral step-down drug candidates with the potential to treat a wide range of serious bacterial infections. The company is well positioned to create significant value in the years ahead.”

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals is a clinical stage biopharmaceutical company utilizing its breakthrough synthetic chemistry technology platform to discover and develop next-generation tetracycline antibiotics that address unmet needs for serious infections such as drug resistance and gram-negative infections. The company has developed an emerging pipeline of potent novel antibiotics with either broad-spectrum activity or activity more narrowly focused by indication that provide a complementary portfolio of intravenous and oral drug candidates with the potential to treat a wide range of infections. To learn more about Tetraphase, please visit www.tphase.com.



CONTACT:

Tetraphase Pharmaceuticals
David Lubner, 617-715-3551
SVP, CFO

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.